卵巢功能抑制联合芳香化酶抑制剂治疗绝经前乳腺癌的短期预后效果评价  

Evaluation of short-term prognosis of OFS combined with AI in the treatment of premenopausal breast cancer

作　　者：王存富 钱朋飞[1] 曾懿 邱国芳 邓素华[1] WANG Cun-Fu;QIAN Peng-Fei;ZENG Yi(Department of Breast Surgery,Huizhou Third People's Hospital,Huizhou 516001,Guangdong,China)

机构地区：[1]惠州市第三人民医院乳腺外科,广东惠州516001

出　　处：《吉林医学》2024年第6期1307-1310,共4页Jilin Medical Journal

基　　金：惠州市科技计划项目[项目编号:2021WC0106199]。

摘　　要：目的:分析卵巢功能抑制与芳香化酶抑制剂联合应用于绝经前年轻乳腺癌治疗中的临床价值。方法:选取惠州市第三人民医院乳腺外科2020年4月~2021年10月收治的60例绝经前乳腺癌患者为研究对象,根据治疗方案的不同将患者分为试验组和对照组各30例。对照组使用他莫昔芬治疗,试验组采用卵巢功能抑制联合芳香化酶抑制剂治疗,比较两组的治疗效果。结果:试验组骨质疏松、关节痛、阴道不规则出血、胃肠道反应等不良反应发生率均低于对照组,差异有统计学意义(P<0.05)。化疗结束后6个月,试验组卵巢功能恢复率(93.33%)高于对照组(73.33%),差异有统计学意义(P<0.05),化疗结束后12个月两组卵巢功能恢复率比较,差异无统计学意义(P>0.05)。试验组化疗6个月、12个月的卵巢囊肿发生率和子宫内膜增厚率均低于对照组,差异有统计学意义(P<0.05),化疗3个月两组比较差异无统计学意义(P>0.05)。结论:卵巢功能抑制联合芳香化酶抑制剂联合方案治疗绝经前乳腺癌的近期效果优于他莫昔芬单独治疗方案。Objective To analyze the clinical value of combination of ovarian function inhibition and aromatase inhibitor in the treatment of premenopausal young breast cancer.Method 60 premenopausal breast cancer patients admitted to our hospital from April 2020 to October 2021 were selected as research object.According to different treatment schemes,the patients were divided into experimental group and control group,with 30 cases in each group;The control group was treated with tamoxifen,and the experimental group was treated with ovarian function inhibition combined with aromatase inhibitor.The therapeutic effects of the two groups were compared.Results The incidence of adverse reactions such as osteoporosis,arthralgia,irregular vaginal bleeding and gastrointestinal reactions in the experimental group was lower than that in the control group(P<0.05).Six months after the end of chemotherapy,the ovarian function recovery rate of patients in the experimental group was 93.33%,which was higher than 73.33%of the control group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the recovery rate of ovarian function between the two groups 12 months after chemotherapy(P>0.05).The incidence of ovarian cyst and endometrial thickening of patients in the experimental group after 6 and 12 months of chemotherapy were lower than those in the control group(P<0.05).There was no statistically significant difference between the two groups after 3 months of chemotherapy(P>0.05).Conclusion The short-term effect of ovarian function inhibition combined with aromatase inhibitor in the treatment of premenopausal breast cancer is better than that of tamoxifen alone,which is worthy of clinical reference.

关 键 词：绝经前乳腺癌 卵巢功能抑制 芳香化酶抑制剂 他莫昔芬 

分 类 号：R737.9[医药卫生—肿瘤]